Search Results 2201-2210 of 16178 for Epilepsy (Partial Onset)
There are also less common very early (phase 0) and later (phase 4) phases. ... duration of the study, and at least 30 days after discontinuing study drug.
There are also less common very early (phase 0) and later (phase 4) phases. ... duration of the study. Participants who do not have financial resources to ...
... epilepsy. Analyses of Metabolic Agents Following Brain Radiation. Rochester, Minn. The purpose of this study is to determine the feasibility of serial ...
Meyer, M.D.. Neurosurgeon. Rochester, MN. Areas of focus: Epilepsy surgery, Brain tumor surgery, Awake brain surgery, Pituitary tumor surgery, Trigeminal ...
Participants with AD duration of at least 3 months (participant/parent/guardian may verbally report signs and symptoms of AD with onset at least 3 months prior) ...
Subjects on GSK2330672 will also receive placebo tablets to maintain blinding. The total duration of a subject's participation will be up to 45 days of ...
Multi-center, randomized, double-blind, placebo-controlled trial to evaluate the efficacy of abatacept to achieve sustained glucocorticoid-free remission in ...
... epilepsy. 2. Age 18 – 65. Exclusion Criteria: 1. Patients who have cognitive impairments that would limit their ability toparticipate in the memory testing. 2 ...
Participation eligibility · Diagnosis of secondary or atypical parkinsonism. · Onset of any parkinsonian motor sign or symptom > 5 years before Screening Visit.
Pediatric patients with ongoing seizures and/or neurological abnormalities;; Hemodynamically unstable patients;; Complex clinical situations requiring medical ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Make a gift before July 31 and it can be doubled in impact thanks to a $100,000 Summer Challenge.